Abstract-It is known that hyperaldosteronism has been associated with magnesium deficiency, yet there are no data on the intracellular concentration of ionized magnesium ([Mg   2ϩ i ]) in subjects with primary aldosteronism (PA). We measured intralymphocyte free magnesium ([Mg 
2ϩ i ]) in subjects with primary aldosteronism (PA). We measured intralymphocyte free magnesium ([Mg Key Words: aldosterone Ⅲ ions Ⅲ magnesium Ⅲ calcium Ⅲ lymphocytes Ⅲ hypertension P rimary aldosteronism is a volume-dependent form of hypertension that is the subject of increasing interest. Studies aim to elucidate the cellular events resulting from in vivo aldosterone action. With regard to ion membrane transport systems, an increased activity of membrane Na ϩ -H ϩ exchanger 1,2 and increased plasma amounts of an Na ϩ -K ϩ pump inhibitor have been described in primary aldosteronism. 3 It has long been known that cases of hyperaldosteronism are characterized by magnesium deficiency, yet the data that could explain this phenomenon are extremely limited and contrasting and refer exclusively to levels of plasma and urinary magnesium. This is a limiting factor when we consider the fact that Ͼ99% of total body magnesium is located intracellularly.
Aldosterone is believed to influence renal magnesium handling, causing magnesium wasting, 4 although there is disagreement regarding this finding. 5 The acute administration of mineralocorticoids fails to modify magnesium and calcium excretion in humans, 5 but certain clinical and experimental data suggest that the excretion of calcium and magnesium may be affected by the long-term action of mineralocorticoids. 4 It has also been suggested that magnesium operates as a regulator of the production of aldosterone. Indeed, the infusion of magnesium suppresses plasma aldosterone levels in humans, 6, 7 high levels of magnesium decrease aldosterone production in cultures of rat zona glomerulosa cells, 8 and experimental magnesium deficiency stimulates aldosterone production.
Very little data are available on plasma magnesium in subjects with primary aldosteronism. In 1954, Mader and Iseri 9 reported the case of a patient with corticosterone-like mineralocorticoid hypersecretion with hypomagnesemia. In 1962, Horton and Biglieri 4 described the cases of 5 patients with primary aldosteronism and an increased renal magnesium clearance despite normal plasma magnesium levels. More recently, Resnick and Laragh 10 described the cases of 10 patients with primary aldosteronism who had normal plasma magnesium values.
There also are no data concerning the possible effects of aldosterone on the cellular homeostasis of magnesium; thus, no data are available so far relating [Mg 12 After hospitalization, the diagnosis of primary aldosteronism was made for all the patients on the basis of a complete clinical, laboratory, and instrumental examination. The diagnosis of primary aldosteronism caused by aldosterone-producing adenomas or bilateral adrenal hyperplasia was made with the use of computed tomography scanning and bilateral adrenal vein sampling. In this way, we sought to detect aldosterone, renin, and cortisol levels; the latter was used to confirm the accuracy of catheter placement in the adrenal vein. Particular care was taken to exclude patients with chronic alcoholism and diabetes because these 2 pathological conditions are associated with magnesium wasting. 16, 17 The study was approved by the local ethics committee, and the subjects gave informed consent.
The blood samples used for the determination of lymphocyte [Mg i ] were taken from patients and control subjects in the morning after overnight fasting. All forms of drug treatment were discontinued Ն3 weeks before the samples were taken. Because diuretics are known to affect Mg 2ϩ i levels, 18 patients receiving such treatment at any time were excluded from the study. All subjects were on an unrestricted diet.
Routine Laboratory Tests
Total plasma calcium, sodium, and potassium levels were measured with an autoanalyzer (Technicon DAX 96; Miles Inc), as were total plasma magnesium and calcium levels (Hitachi 911 Analyzer; Hitachi Ltd). Total urinary magnesium and calcium, sodium, and potassium levels were measured with the use of flame photometry. Plasma renin, aldosterone concentration, and urinary aldosterone were measured with radioimmunoassay. 19, 20 We used the method previously described. 12 Briefly, peripheral blood lymphocytes were isolated through Ficoll sedimentation, resulting in cell preparations with a percentage of lymphocytes of i ] was carried out according to the procedures described earlier.
Measurement of [Mg
To limit the possibility of artifacts, the hormones tested in vitro on the lymphocytes were not added directly to the test-tube during reading from the spectrofluorometer. We chose another strategy, which involved isolation of the lymphocytes with Ficoll and the subsequent conduction of 2 or more parallel experiments with cells from the same donor, which were incubated with only the vehicle of the hormone (control) or the hormone, respectively.
Statistical Analysis
Results are expressed as meanϮSD. Because no evidence of nonnormal distribution or inequality of variances was present in the variables considered, comparison between groups was performed with Student's t test and considered statistically significant when the probability of the null hypothesis was Յ5%. Confidence intervals for differences in mean values were also provided. To determine differences between groups, a 1-way ANOVA was used. Correlations between 2 variables were studied with the use of the linear regression method.
Results

Main Clinical and Metabolic Variables
Total plasma magnesium, daily urinary magnesium excretion, and total plasma calcium did not differ significantly between patients with primary aldosteronism and normotensive controls (Table) . Plasma potassium and plasma renin levels in the upright position were significantly reduced in patients with primary aldosteronism compared with normotensive control subjects. Plasma aldosterone levels in the upright position together with daily urinary aldosterone excretion were significantly increased in patients with primary aldosteronism compared with normotensive control subjects.
[Mg Figure 2 shows the time course of action of aldosterone on these cells. The effect is visible after 30 minutes and reaches a maximum level after Ϸ2 hours, after which it remains more or less stable until the fifth hour. After 5 hours, the fall in [Mg 2ϩ i ] is equal to 50% of the initial level. Figure 3 shows the effect of aldosterone (1 mol/L) on the decrease in [Mg 2ϩ i ] is completely antagonized by canrenoic acid (15 mol/L) and by inhibitors of transcription (50 g/mL actinomycin D) and protein synthesis (15 g/mL cycloheximide) (meanϮSD; controls nϭ6, 100Ϯ8%; aldosterone nϭ6, 63Ϯ8%; aldosterone and canrenoic acid nϭ6, 99Ϯ6%; aldosterone and cycloheximide nϭ6, 98Ϯ7%; aldosterone and actinomycin D nϭ6, 98Ϯ6%). Figure 4 shows the dose-effect curves of the decrease in [Mg 
Discussion
Primary aldosteronism represents an interesting model for the study of the physiopathology of aldosterone. The in vivo influence of aldosterone on Mg 2ϩ i has been hypothesized, but cellular measurements have not been performed. Aldosterone is thought to act at renal level through the inducement of renal tubular magnesium excretion, 4 although this is still a matter of debate. 5 This probably occurs secondary to the volume expansion and hypertension associated with hyperaldosteronism because magnesium reabsorption is related to tubular flow rates and sodium reabsorption, both of which are altered in this situation. Horton and Biglieri described significantly increased magnesiuria in patients with primary aldosteronism, 4 but other authors have not confirmed these findings. 5 In our group of patients, daily urinary magnesium excretion was not statistically different from that of control subjects.
Regarding magnesium plasma levels, most data from the literature indicate that they are not significantly altered in patients with primary aldosteronism, 4,10 and our results are in accordance with previous data. Despite this fact, Resnick and Laragh 10 reported that although serum magnesium values in their subjects with primary aldosteronism were within normal limits, they were significantly higher than those in normotensive control subjects. They believe that this is in keeping with the hypothesis that low-renin hypertension has a distinctive magnesium and calcium profile. 22 We must point out that Resnick et al 22 refer to plasma ionized magnesium as opposed to plasma total magnesium, which was measured in the present study. Despite a modest overlap, we found that mean [Mg i ], but the majority of the patients showed a significant decrease in ionized magnesium. No significant differences were found between patients with adrenal hyperplasia and patients with aldosterone-producing adenomas.
From these data on patients with primary aldosteronism, it is not possible to explain the physiopathological mechanism underlying the Mg 2ϩ i deficiency. In particular, we were not able to demonstrate any significant correlation between [Mg 2ϩ i ] and renal magnesium excretion or with renin or aldosterone plasma and urinary levels, and we can neither confirm nor exclude a cause-effect relationship.
In consideration of the questions raised by these ex vivo results, we studied the effect in vitro of aldosterone on lymphocytes. In vitro, aldosterone decreases the content of basal ionized magnesium by Ϸ45% to 50%, which is a highly significant reduction. The effect of aldosterone appears to be mediated by the specific receptor of the hormone in that the decrease in [Mg 2ϩ i ] is not observed when canrenoic acid, a specific antagonist of the receptor, is present. Moreover, the effect of the hormone seems to involve the classic genomic pathway of steroid action because it is completely eliminated by actinomycin D and cycloheximide, inhibitors of transcription and protein synthesis, respectively. The effects of aldosterone on the intralymphocyte contents of ionized magnesium appear to be dose dependent with an EC 50 value of Ϸ0.5 to 1 nmol/L aldosterone. This value is close the physiological concentration of plasmatic aldosterone (0.5 nmol/L) and suggests that aldosterone may play a role as physiological regulator of the Mg 2ϩ i content. Cortisol and progesterone, which were tested because of their close biochemical simi- larity, also reduce [Mg 2ϩ i ] but only at higher concentrations, as shown by their respective EC 50 values, which appear to be higher than that of aldosterone. Finally, the experiments carried out without extracellular sodium suggest a possible mechanism through which the cellular action of aldosterone operates. In fact, in the absence of sodium on the outside of the plasmatic membrane, the activity of the Na ϩ -Mg 2ϩ antiporter, the principal known mechanism of magnesium efflux, 23 is inhibited. Under these conditions, the action of aldosterone is no longer measurable. The action of aldosterone on [Mg antiporter of the plasmatic membrane. There seems to be a different mechanism to explain the negative magnesium balance in cases of hyperaldosteronism, an alternative to the hypothesis that attributes the stimulus to increase renal clearance of the ion to the chronic volume expansion. 5 Moreover, the EC 50 values found for the effect of aldosterone on [Mg i ] may play a role in the pathogenesis of arterial hypertension in primary aldosteronism in that it is well known that in vitro magnesium deficiency is followed by an increase in vascular tone and potentiates the pressor effect of angiotensin II. 24 Despite this fact, the link between magnesium homeostasis and blood pressure regulation remains controversial.
Finally, although it was not the principal issue of our study, we measured total plasma calcium as well as [Ca 2ϩ i ]. We did not find any statistically significant differences in total calcium plasma levels and [Ca 2ϩ i ] between patients with primary aldosteronism and normotensive control subjects. Our results, which are limited to total calcium plasma levels, are in agreement with those of Resnick and Laragh. 10 In conclusion, we have shown, for the first time, an Mg 2ϩ i deficiency in patients with primary aldosteronism. Moreover, this hormone shows in vitro a specific effect on the cell model by significantly decreasing [Mg i ] via a mechanism that is probably genomic. It is therefore possible to hypothesize that the magnesium deficiency found in subjects with primary hyperaldosteronism is related to a direct effect of aldosterone on the cells. Furthermore, the EC 50 value for the action of aldosterone on [Mg 
